Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Rheumatology
•
Hematology
•
Rituximab
•
Hepatitis B
•
General Rheumatology
•
Infectious Disease
•
Immunosuppression
•
Hepatology
In a patient with negative Hep B surface Ag, Hep B surface antibody+, and Hep B core antibody+ serologies, do you initiate antiviral prophylaxis (e.g. entecavir) prior to starting rituximab?
Related Questions
Do you routinely consider FDG PET/CT imaging for workup of fever of unknown origin?
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
In light of recent measles outbreaks, have you adjusted your vaccination counseling or preventive strategies for adult immunocompromised patients?
Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?
How often do you see bony erosions in patients with Lyme arthritis?
Do you continue TNF inhibitors in patients with a new diagnosis of CLL?
What is your re-immunization strategy after auto SCT for patients with myeloma on dara/len maintenance?
How do you approach management of DMARDs and biologics in a patient with active RA, but frequent recurrent simple UTIs?
How do you approach recurrent migratory superficial thrombophlebitis in a patient with a negative malignancy workup and low-titer anticardiolipin antibodies?
How would you treat an asymptomatic patient with a positive Blastomyces antibody, evidence of prior granulomatous lung disease on imaging, and who may require immunosuppression in the future?
